Alzheimer's disease (AD) is defined by progressive impairments in memory and cognition and by the presence of extra-cellular neuritic plaques and intracellular neurofibrillary tangles. However, oxidative stress and impaired mitochondrial function always accompany AD. Mitochondria are a major site of production of free radicals [i.e., reactive oxygen species (ROS)] and primary targets of ROS. ROS are cytotoxic, and evidence of ROS-induced damage to cell membranes, proteins and DNA in AD is overwhelming. Nevertheless, therapies based on antioxidants have been disappointing. Thus, alternative strategies are necessary. ROS also act as signaling molecules including for transcription. Thus, chronic exposure to ROS in AD could activate cascades of genes. Although initially protective, prolonged activation may be damaging. Thus, therapeutic approaches based on modulation of these gene cascades may lead to effective therapies. Genes involved in several pathways including antioxidant defense, detoxification, inflammation, etc. are induced in response to oxidative stress and in AD. However, genes that are associated with energy metabolism, which is necessary for normal brain function, are mostly down-regulated. Redox sensitive transcription factors such as activator protein-1 (AP-1), nuclear factor κB (NF-κB), specificity protein-1 and hypoxia-inducible factor (HIF) are important in redox-dependent gene regulation. PPARγ co-activator (PGC-1α) is a co-activator of several transcription factors and is a potent stimulator of mitochondrial biogenesis and respiration. Down-regulated expression of PGC-1α has been implicated in Huntington's disease (HD) and in several HD animal models. Its role in regulation of ROS metabolism makes it a potential candidate player between ROS, mitochondria and neurodegenerative diseases. This review summarizes the current progress on how oxidative stress regulates the expression of genes that might contribute to AD pathophysiology and the implications of the transcriptional modifications for AD. Finally, potential therapeutic strategies based on the updated understandings of redox state-dependent gene regulation in AD are proposed to overcome the lack of efficacy of antioxidant therapies.
KeywordsOxidative stress; transcription factors; Kreb's cycle; redox; metabolism; Alzheimer's disease
Oxidative stress and Alzheimer's diseaseAD is defined by progressive impairments in memory and cognition and by the presence of extracellular neuritic plaques and intracellular neurofibrillary tangles. β-amyloid peptide (Aβ) is the major component of the plaque, while the tangles are composed of hyperphosphorylated tau proteins. Since these three features define AD, any hypothesis Address correspondence to: Qingli Shi, Dept. of Neurology and Neuroscience, Weill Medical College of Cornell University, Burke Medical Research Institute, 785 Mamaroneck Ave., White Plains, New York 10605, USA, Tel: 914-368-3129; Fax: 914-597-2757.cornell.edu.
NIH Public Access
Author ManuscriptAlzheimer Dis Assoc Disord. Author...